Cytokinetics EVP, Chief Commercial Officer Andrew Callos disposes of 15,000 common shares for $1.11 million
Cytokinetics, Incorporated CYTK | 0.00 |
- Cytokinetics EVP and Chief Commercial Officer Andrew Callos exercised non-qualified stock options for 15,000 shares on June 1, 2026 at USD 23.26.
- Callos sold 15,000 shares the same day at USD 74.08.
- He ended the day with 58,555 shares of common stock directly owned.
- He also reported 39,000 stock options beneficially owned following the transaction.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000065), on June 01, 2026, and is solely responsible for the information contained therein.